Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL34465814 | 0.80 | FGFR1 (0.42) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL4059255 | 0.75 | FGFR1 (0.53) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL29593970 | 0.75 | FGFR1 (0.53) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL256337 | 0.75 | FGFR1 (0.53) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL18330920 | 0.75 | FGFR1 (0.53) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL25291568 | 0.75 | FGFR1 (0.53) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL5030414 | 0.72 | FGFR1 (0.46) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL277760 | 0.71 | TDP1 (0.54) | FGFR1LMNAHPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL1701476 | 0.71 | FGFR1 (0.49) | FGFR1LTA4HALDH1A1KDM4EMKNK1 | |
| SCHEMBL1106481 | 0.71 | FGFR1 (0.49) | FGFR1LTA4HALDH1A1KDM4EJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2025-05-27 | — | — | US | disclosed |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | disclosed |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 2009-10-29 | — | — | US | disclosed |
| WO-2007047793-A2 | CYCLOPENTENOL NUCLEOSIDE COMPOUNDS, INTERMEDIATES FOR THEIR SYNTHESIS AND METHODS OF TREATING VIRAL INFECTIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-5446139-A | Purine analog nucleoside and nucleotide compounds | BOEHRINGER MANNHEIM GMBH (DE) | 1995-08-29 | — | — | US | disclosed |
| EP-0038568-B1 | SYNTHESIS OF DEAZAPURINE NUCLEOSIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1983-07-20 | — | — | EP | disclosed |
| US-4347315-A | FORMING 4-SUBSTITUTED 1-B-D-RIBOFURANOSYL-1H-IMIDAZO(4,5-C)PYRIDINES FROM RIBOSE-1-PHOSPHATE | BURROUGHS WELLCOME CO. (US) | 1982-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12312353-B2 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | FGFR1 4459/4885LTA4H 4414/4885ALDH1A1 3642/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | FGFR1 4459/4885LTA4H 4414/4885ALDH1A1 3642/4885 |
| US-20090270431-A1 | Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections | REV1, NSUN2, ORC3 | FGFR1 2172/4885LTA4H 1759/4885ALDH1A1 1749/4885 |
| US-20230002388-A1 | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | NSD2, NSD1, NSD3 | FGFR1 4459/4885LTA4H 4414/4885ALDH1A1 3642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.